EGFR and non-small cell lung carcinoma: In NSCLC, various biomarkers have been proposed as MRD biomarkers, such as epidermal growth factor receptor (EGFR) mutations, K-ras mutations and excision repair cross-complementation group 1 (ERCC-1) expression, but further research is required before being utilised in the clinical trial.